Decreased appetite: Occurs in about 6% (7 mg) to 9% (14 mg) of patients, compared to 1% on a placebo
Truong B, Allegri G, Liu XB, Burke KE, Zhu X, Cederbaum SD, Hberle J, Martini PGV, Lipshutz GS (2019) Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency
placebo over 52 weeks Efficacy observed both as monotherapy or combined with antifibrotics Well-tolerated, reduced death risk, though did not show statistically significant survival benefit Why it matters: Anti-inflammatory mechanism differentiates JASCAYD from existing antifibrotics (nintedanib, pirfenidone) Reinforces Boehringers leadership in respiratory innovation and re-energizes IPF R&D after years of limited breakthroughs Follow our page for more such updates: News Source: #FDAApproval #IPF #PulmonaryFibrosis #Respiratory #RespiratoryMedicine #DrugDevelopment #BoehringerIngelheim #Ofev #Esbriet #PharmaInnovation To view or add a comment, sign in PYC today announced that we have initiated a global repeat dose study of PYC-001 in patients with ADOA (known as the MYRTLE study) and that the first subject in this clinical trial has now received their initial dose of PYC-001 - The objective of the MYRTLE study is to evaluate the safety/tolerability and efficacy profile of repeat dosing of PYC-001 in the ADOA population with a view to establishing clinical proof of concept for the drug candidate prior to initiation of a registrational study - Data from the Myrtle study across both safety/tolerability and efficacy endpoints is expected to be available in H2 2026 Read the full announcement here: To view or add a comment, sign in First new therapy for IPF in over 10 years
You can read the full article at The worldwide obesity epidemic is accompanied by a higher incidence of cardiovascular disease (CVD), specifically stroke and heart attacks
